摘要
妊娠糖尿病的发病率逐年升高，其与妊娠期不良反应及母婴预后相关。目前对于妊娠糖尿病的治疗存在争议。因考虑其安全性，胰岛素治疗仍然是妊娠糖尿病药物治疗首选。最近的研究显示，超短效胰岛素类似物（赖脯胰岛素、门冬胰岛素）及口服降糖药物，主要是格列本脲及二甲双胍，同样安全、有效。但仍旧缺乏长效胰岛素类似物安全性的证据。
The incidence of gestational diabetes mellitus （GDM） is increasing. GDM is associated with adverse pregnancy outcomes and has long-term implications for both mother and child. The management of GDM is still controversial. As insulin therapy is effective and safe, it is considered as the first choice of pharmacotherapy for GDM. Recent studies have shown that the short acting insulin analogs such as lispro and aspart, and oral anti-diabetic agents such as glyburide and metfonnin, are safe, but there are only limited data to support the use of long acting insulin analogs.
出处
《国际内分泌代谢杂志》
2011年第2期97-99,共3页
International Journal of Endocrinology and Metabolism
关键词
妊娠糖尿病
胰岛素类似物
口服降糖药物
Gestational diabetes mellitus
Insulin analogs
Oral anti-diabetic agents
